港股異動 | 中生製藥漲逾4% 維格列汀片獲藥品註冊批件
格隆匯4月17日丨中生製藥(1177.HK)現報11.64港元,漲4.11%,暫成交3.2億港元,最新總市值1465億港元。中生製藥昨日晚間公佈,集團開發的新型口服降糖藥物維格列汀片已獲得中國國家藥品監督管理局頒發藥品註冊批件。維格列汀是一種新型的口服降糖藥,該藥品有良好的應用前景,目前已在多個國家上市。此一重要口服降糖藥獲批,將進一步加強和鞏固集團在糖尿病領域的優勢地位,與已有上市品種形成產品組合,共同深耕市場潛力巨大的慢病治療領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.